Single study results showed that SGLT2-Is vs. placebo reduced the risk of incident or worsening nephropathy in White and Asian populations but not in the Black population: HRs (95% CIs) of 0.57 (0.48–0.67), 0.63 (0.49–0.81) and 1.01 (0.58–1.75), respectively (Supplementary Appendix 12). Here, SLC5A2 is linked to Nephropathy.